Ulf Göran Richenberg

Scribona AB manufactures and distributes computers, operating systems, servers, and network products. The company's principal activities are the retail and distribution of computer products and high-tech office equipment such as PCs, handheld devices, printers, software and accessories.The company produces office products, office electronics information services in the Nordic countries. The company has five subsidiaries in Sweden, Luxemburg, UK, Finland and Norway. The company was founded in 1992 and is headquartered in Stockholm, Sweden

Esselte AB manufactures office solutions. It sells office products and graphics products. The company was founded on April 18, 1913 and is headquartered in Solna, Sweden.

Vattenfall AB engages in the generation, distribution, and sale of heat and electricity. It operates through the following segments: Heat, Customers and Solutions, Wind, Power Generation, and Distribution. The company was founded in 1909 and is headquartered in Solna, Sweden.

NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden.

Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities.